Experts discuss the synergies and implementation of state-of-the-art hybrid PET/MR technology and the new avenues of exploration it affords in the fields of neuroscience, cancer, and metabolic disease through to dual molecular probe development.

Positron emission tomography (PET) combined with magnetic resonance imaging (MRI) is a hybrid technology that brings together molecular sensitivity & specificity, morphologic and functional imaging to enable simultaneous, complimentary small animal imaging that does not alter the physiological state. This complimentary, simultaneous imaging opens new areas to explore across various fields including neuroscience, cancer, metabolic disease, and molecular probe development. PET/MR combines the fields of nuclear medicine, molecular imaging and radiology to provide simultaneous, complementary small animal imaging that does not alter physiological parameters.

In this Bruker webinar, preclinical molecular imaging experts Peter Caravan and Michael Heidenreich will discuss the synergies of this hybrid technology and the new avenues of exploration it opens up across areas ranging from neuroscience, cancer, and metabolic disease through to dual molecular probe development. The implementation of state-of-the-art hybrid PET/MR technologies will be discussed with a focus on the PET Insert Si198 for mice and rats, applications using the Bruker BioSpec 47/40 PET/MR, and the introduction of the new PET Insert Si103 for mice and rat head applications using small bore Bruker MRI scanner.

Key Topics Include:

  • New applications enabled by PET/MR across areas including oncology, neuroscience, metabolic diseases, and molecular probe development
  • Implementation of state-of-the-art hybrid PET/MR technologies
  • First results and introduction timeline of the new “PET Insert Si 103”

Presenters

Co-Director
Institute for Innovation in Imaging (I3)
Massachusetts General Hospital

Peter Caravan, PhD, is co-director of the Institute for Innovation in Imaging (I3) at Massachusetts General Hospital and an Associate Professor of Radiology at Harvard Medical School. He leads a multidisciplinary and translational molecular imaging lab (the Caravan Lab) focused on the invention of novel molecular probes and their broad applications in cardiovascular, pulmonary, renal and hepatic diseases, as well as in cancers. His research spans novel chemistry technologies from advanced MRI and PET imaging in animal models to applications in patient populations. He holds Investigational New Drug (IND) applications for a fibrin-targeted PET tracer and a collagen-targeted PET tracer that are currently being evaluated in 6 clinical trials. He has invented molecular probes specific to fibrogenesis, acidosis, inflammation and thrombosis, as well as gadolinium-free MR contrast agents.

Vice President Nuclear Molecular Imaging
Bruker BioSpin

Michael received his PhD in C13 MRI imaging from the University of Ulm and joined Bruker in 1999 as an MRI application scientist. In 2005, he was appointed Productline Manager and has been responsible for Brukers BioSpec MRI imaging products for more than 10 years. Since 2016, he is managing the Nuclear Molecular Imaging Business Unit for PET/SPECT/CT and PET/MR imaging solutions with its main R&D and application teams in Valencia/Spain, Kontich/Belgium, Billerica/US and Ettlingen/Germany.

Production Partner

Bruker BioSpin

Bruker offers preclinical imaging solutions for a broad spectrum of application fields, such as cancer research, neuroimaging and cardiac disease.

Bruker BioSpin

Additional Content From Bruker BioSpin

Related Content

Ensuring Quantitative Accuracy in PET

Ensuring Quantitative Accuracy in PET

NMI experts describe quality control procedures and image corrections for the Bruker PET technology, demonstrate image transfer to PMOD for analysis and outline best practices to ensure good quantitative PET.